Main Article Content


In the present study, the antidiabetic formulation was evaluated for the invitro antidiabetic, antioxidant and a pilot invivo study was conducted with a mixture of herbal powders, i.e. Mimosa pudica L and Aegle marmelos (L) Corr. The formulation was screened for its antioxidant activity using DPPH free radical assay and inhibitory effect against the α- glucosidase and lipase compared with the standard. Assays were carried out at the concentration varying from 50 – 500 µg/ml (antioxidant activity) and 20 – 100 µg/ml (antidiabetic). Results of the present study have clearly indicated that the formulation possesses significant α-glucosidase enzyme inhibition property ranges from 41.4% - 12.42% in the different concentration of aqueous extract and similarly pancreatic lipase inhibition potential at 50% with value of 100µg /ml revealed the significant activity. Moreover, the formulation administered in the diabetic patient reduces the glucose level of fasting and postprandial level, notably; thus, it indicates that it is a promising drug candidate that proves antidiabetic activity.


Mimosa pudica Aegle marmelos Antidiabetic formulation Diabetes mellitus

Article Details

How to Cite
Anitha V, Rajarajeswari, Bupesh G, Vasanth S, Tirumalai Vasan P, Sahoo U, & Pitambar Humane. (2020). Therapeutic Efficacy of Mimosa Pudica - Aegle Marmelos formulation on Diabetes Mellitus. International Journal of Research in Pharmaceutical Sciences, 11(3), 4089-4094.